Detection of a new mutant α-1-antichymotrypsin in patients with occlusive-cerebrovascular disease  by Tsuda, Michio et al.
Volume 304, number 1, 66-68 FEBS 11124 
Q 1992 Federation of European Biochemical Societies 00145793/92/85.00 
June 1992 
Detection of a new mutant a-1-antichymotrypsin in patients with 
occlusive-cerebrovascular disease 
Michio Tsuda”, Yukari Se?‘, Masaichi Yamamura”, Masahiro Yamamotob and Yukito Shinoharab 
uPepartmetit of Bioclternisrry and bDepartntettt of Neurology, Tokai University, Moo/ of Medicinr. Mtara, Kartagawa, 259-11, 
Japan 
Received 27 March 1992; revised version received 21 April 1992 
A new mutant n-l -antichymotrypsin (variant ACT) was found by direct sequencing and PCR-single strand conformation polymorphism (PCR- 
SSCP). This variant ACT was a point mutation ofexon V of ACT, with the substitution of Met by Val. Four out of six individuals with this variant 
ACT had occlusive-cerebrovascular disease. leading to one hypothesis that there might bc an association between this mutation and occlusive- 
cerebravascular disease, 
a-l-Antichymotrypsin; Variant cr.I-antichymotrypsin; PCR-SSCP; Occlusive-cerebrovascular disease 
1 a INTRODUCTION 
The glycoprotein Q- 1 -antichymotrypsin [ACT) is an 
acute phase protein and present in normal human 
serum at high concentration (294 f 44ydml). However 
the physiological activity of ACT is not yet known, 
although it has been reported that ACT inhibits the 
activity of pancreatic chymotripsin and elastase, 
human neuttophil cathepsin G and mast cell chymase 
[I]. ACT has also been shown to increase the number 
of anti-sheep erythrocyte antibody producing cells in 
mice [2] and to inhibit cellular lysis mediated by cyto- 
toxic T lymphocytes and cell-medited cytotoxicity 
(ADCC) in vitro [33. We also reported that ACT has the 
ability to bind DNA [4] and inhibits purified DNA 
polymerasc a [5] and DNA primase [6’]. Recently it has 
been shown that ACT is present in senile plaque in the 
brain, particularly in the hypocampus of Alzheimer’s 
disease patients 171, in which the concentration of ACT 
in cerebra-spinal fluid increased [B], suggesting that 
ACT plays a role in the formation of senile plaque in 
Alzheimer’s disease. From these properties of ACT, it 
is possible to consider that ACT participates in the reg 
ulation of the biological response including inflamma- 
tory reactions, connective tissue damage, nnaphylaxic 
reactions and the regulation of immune response, cell 
growth and so on. Therefore qualitative and quantita- 
tive change of ACT is considered to cause some dys- 
function of’ the physiological response, resulting in spe- 
cific diseases. We report here a variant ACT frequently 
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found in patients with occlusive-cerebrovascular dis- 
ease. 
2. MATERIALS AND METHODS 
2.1. PCR contiitiotu and sequencing 
PCR was carried out using the following primers: 5’.TTACTGA- 
GAGCCCCACTGCATGAT3’ and S’CATAAGGCTGTGC’ITG- 
ATGTA-3’. 
PCR conditions were 94°C for 2 min to denature, then 35 cycles of 
94OC for I min. 55OC for 1 min. 72°C for 2 min, and a single cycle 
of 72°C for 5 min. The reaction volumeof ICKIyl containing 100 pmol 
primers. dNTPs at 200,uM. MgCI, at 1,s mM and O.Spg of lcucocyle 
genomic DNA. After 2% agarose lectrophoreais, the PCR product 
was extracted and a second PCR was performed as the first one. The 
second PCR product was purified on a ULTRAFREE (C3TK, Mil- 
liporc) and used for sequencing with a Scquenase kit (version 2.0) 
(USB) following the manufacturer’s protocol. 
2,2. PCR-SSCP artuiysis of poim mrrfu~iort 10 es011 Y of ACT gem! 
Primers described above were labelkrl at the 5’ end with IzP and 
used in PCR-SSCPanalysis as described by Orita et al. [9]. Thirty-five 
cycles of the reaction at 94OC, 55°C and 72OC for I min, I min and 
2 min, respectively, were performed, The PCR product (2 ~1) was 
diluted with 40 ~1 of 0.1% sodium dodecyl sulphate and 10 mM 
EDTA. Then 4 ,ul of this solution was mixed with 4 yl of 95% forma- 
mide, 20 mM EDTA, 0.1% Brorr;ophcnol blue, and 0.1% rylcnc cya- 
nol, and heated at 90°C ror 3 min. The denatured PCR product was 
applied to a 6% polyncrylnmidc gel containing 10% glycerol, and 
electrophoresed at room temperature using a fan. 
2.3. BspHL d&esrion of the esw If PCK product 
PCR product (10~1) of exon V was digested with 2 units of f&HI 
(Biolabs) at 37°C for 1 to 2 h, then clcctrophoresed in 3% agarose 
containing ethidium bromide. 
3. RESULTS AND DISCUSSION 
We sequenced the e:xo~! ? of the ACT gene, contain- 
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Fig, 1. Auto~adio~~ph of a scqu~ncin~ gei from the PCR product of exon V of the ACT gene in a normal and an affixted individ~~, showing 
r~ single base pair change in the affected individual (hctcrozygotc). This A to G transition leads to an amino acid substitution of Met by Val at 
codon 389, 
ing the reactive site of this protease inhibitor, in a pa- 
tient with muiti-infarct dementia (MID), Direct se- 
quencing revealed adcnine to guanine transition 
(heterozygote) at base pair 1252 (Fig. 1). This mutation 
causes an amino acid substitution (Met to Val) at codon 
389 close to the reactive site and the carboxy terminal 
of the protease inhibitor. This mutation was detected by 
PCR-single strand conformation polymorphism (PCR- 
SSCP) shown in Fig, 2, so that screening of 95 unrelated 
individuals including healthy subjects (n=32; age, 24-51 
years old), Alzheimer’s disease @=6, age, 62-66 years 
old), occlusive-cerebrovascuiar disease (~32; age, 38- 
80 years old), headache (n=S; age, 42-54 years old) and 
others (multiple sclerosis, epilepsy, Parkinson’s disease 
and so on; n=l7; age, 28-65 years old) was performed 
by PCR-SSCP [9]. Only 6 pruients revealed the muta- 
tion. The PCR product from the normal ACT gene has 
a BspHl restriction site and was ~ompleteiy divested by 
Bs@f (Fig. 3). The PCR products of the genomic DNA 
from individuals with abnormal PCR-SSCP patterns 
were digested with &PHI, It was found that the diges- 
tion was incomplete showing that these PCR products 
have both cutting and non-cutting sites. The sequencing 
of the PCR products with abnormal PCR-SSCP pat- 
Fig, 2. PCR-SSCPanalysis of the point mutation in cxon V of the ACT 
pnc in non~l (XI 3f.d &Wed individuals (A), Thirty-five cycles of 
the reaction at 94’C. 55°C Gnd 72OC for 1 min, 1 min and 2 min, 
respectively, were performed as described in Materiala and Methods. 
PCR products wcrc dcnntured, applied to a 6% polyacryiarnicic pl
confining 10% glycerol, and eI~tfopho~~~ at 2O“C. 
terns confirmed that they were heterozygotes in the 
ACT geene and that the vacant ACT gene was the same 
as described above, with valine substituting methionine. 
Four out of six patients with the variant ACT had oc- 
clusive-cerebrovascular disease (age, 38, 43, 69 and 80 
years old), one suffered from tension-type headache 
(age, 54 years old) and the other one was a healthy 
subject (age, 24 years old). 
This result leads us to one hypothesis that there might 
be an association between this mutation and ocelusive- 
~rebrovascular disease, It is likely that this variant is 
pathogenic, because the variants of the serpin family of 
protease inhibitors have diminished activity or different 
protease specificity. The mutation of the reactive site of 
cr-l-antitrypsin (AT) from Met to Arg at the Pl site 
(Pittsburgh), for example, converts a-I-antit~psin into 
a potent inhibitor of thrombin and factor XI, causing 
a severe bleeding disorder [lo]. 
The properties of this variant ACT may be different 
234bp 
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Fig. 3. &#I digests of the Exon V of the FCR product from normal 
(lane 3) and oflected (lanes 4 and 5) individuals. Lane I, size markers; 
lane 2, not digested, 
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from those of native ACT due to the substitution of Met 
to the more hydrophobic amino acid Val. The function 
of this variant ACT as a potential antifibrinolytic or 
clotting agent is now being studied. 
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